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OBJECTIVES We sought to evaluate the prognostic impact of right ventricular (RV) myocardial involve-
ment in patients with inferior myocardial infarction (MI).
BACKGROUND There is uncertainty regarding the risk of major complications in patients with inferior MI
complicated by RV myocardial involvement. Whether these complications are related to RV
myocardial involvement itself or simply to the extent of infarction involving the left ventricle
(LV) is also unknown.
METHODS We examined the incidence of death and mechanical and electrical complications in patients
with (n 5 491) and without (n 5 638) RV myocardial involvement and in patients with anterior
MI (n 5 971) in an analysis from the Collaborative Organization for RheothRx Evaluation
(CORE) trial. Left ventricular infarct size was assessed by technetium-99m–sestamibi single-
photon emission computed tomography and peak creatine kinase, and LV function was assessed
by radionuclide angiography. We also performed a meta-analysis in which we pooled the results
of our study with previous smaller studies addressing the same question.
RESULTS Six-month mortality was 7.8% in inferior MI compared with 13.2% in anterior MI. Among
patients with inferior MI, serious arrhythmias were significantly more common in patients
with RV myocardial involvement who also had a trend toward higher mortality, pump failure
and mechanical complications. However, this was not associated with a difference in LV
infarct size or function. A meta-analysis of six studies (n 5 1,198) confirmed that RV
myocardial involvement was associated with an increased risk of death (odds ratio [OR] 3.2,
95% confidence interval [CI] 2.4 to 4.1), shock (OR 3.2, 95% CI 2.4 to 3.5), ventricular
tachycardia or fibrillation (OR 2.7, 95% CI 2.1 to 3.5) and atrioventricular block (OR 3.4,
95% CI 2.7 to 4.2).
CONCLUSIONS Patients with inferior MI who also have RV myocardial involvement are at increased risk of
death, shock and arrhythmias. This increased risk is related to the presence of RV myocardial
involvement itself rather than the extent of LV myocardial damage. (J Am Coll Cardiol
2001;37:37–43) © 2001 by the American College of Cardiology
Patients with inferior myocardial infarction (MI) who have
right ventricular (RV) myocardial involvement appear to
have a worse prognosis than those who do not have RV
involvement (1–3). However, previous studies have been
limited by small patient numbers, which has made it difficult
to obtain reliable estimates of the risk of important compli-
cations, such as mortality, mechanical complications (e.g.,
left ventricular [LV] failure and cardiogenic shock) and
serious ventricular arrhythmias. Furthermore, it remains
unclear whether the adverse prognosis in patients with RV
myocardial involvement is simply a reflection of more
extensive LV infarction or whether it may be due to the
presence of RV myocardial involvement itself.
To address these two issues, we examined the incidence
of death, cardiogenic shock, ventricular arrhythmias and
atrioventricular block in patients with (n 5 491) and
without (n 5 638) RV myocardial involvement and in
patients with anterior MI (n 5 971) enrolled in the
Collaborative Organization for RheothRx Evaluation
(CORE) trial. We then pooled our results with previous
smaller studies of RV myocardial involvement to obtain
more reliable estimates of risk. We also assessed LV infarct
size by technetium-99m (99mTc) single-photon emission
computed tomography (SPECT) and peak creatine kinase
(CK), as well as LV function by radionuclide angiography
(RNA), to determine whether these complications were
related to more extensive LV damage or to the presence of
RV myocardial involvement itself.
METHODS
Patients. The CORE trial was a multicenter, randomized,
double-blind, placebo-controlled trial of 2,948 patients with
acute MI who were randomized to receive RheothRx or
placebo. The inclusion and exclusion criteria, study inter-
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ventions and primary efficacy outcomes have been previ-
ously published (4). Briefly, patients presenting within 12 h
of symptom onset and with at least 1-mm ST segment
elevation in two or more contiguous leads or with new
left bundle branch block were eligible for inclusion. Patients
undergoing primary percutaneous transluminal coronary
angioplasty or with renal impairment (creatinine
.2.5 mg/dl) were excluded. All patients gave written,
informed consent, and the study protocol was approved by
the local Institutional Review Boards.
Right ventricular involvement. Myocardial infarction was
diagnosed by at least 1-mm ST segment elevation in at least
two contiguous leads on the baseline electrocardiogram
(ECG): leads V1 through V4 for anterior MI and leads II,
III and aVF for inferior MI. At the time of the baseline
ECG, all centers were prospectively instructed to record
lead V4R in patients with ST segment elevation in leads II,
III or aVF. Right ventricular myocardial involvement was
diagnosed if there was at least 1-mm ST segment elevation
in lead V4R within 12 h of symptom onset. Of 1,599
patients randomized with acute inferior MI, 1,129 (71%)
had lead V4R analysis performed; RV status was unknown in
the remaining 470 patients (29%).
LVinfarct size and ejection fraction. A subset of clinical
centers participating in the CORE trial performed addi-
tional laboratory studies to assess LV infarct size by 99mTc-
sestamibi SPECT, as well as LV end-systolic volume and
LV ejection fraction by RNA. Peak CK was also measured
to further assess LV infarct size. The SPECT and RNA
studies were completed between days 6 and 16 after the
acute MI in 1,167 (40%) and 1,199 (41%) patients, respec-
tively. The SPECT and RNA studies were analyzed by
central core laboratories.
Statistical analysis. Baseline characteristics in patients
with and without RV myocardial involvement and in
patients with anterior MI were compared using the chi-
square test for categoric variables and the t test for contin-
uous variables. The incidences of death, pump failure and
mechanical and electrical complications were compared
after adjustment for age, gender and differences in baseline
characteristics, using multivariable logistic regression. A
two-tailed p value ,0.05 was considered as suggestive
evidence and a two-tailed p value ,0.01 was considered as
persuasive evidence of a difference not due to chance alone.
Differences in infarct size by SPECT and peak CK, and in
LV ejection fraction and LV end-systolic volume, among
the groups were analyzed by one-way analysis of variance.
Multivariable logistic regression was used to identify pre-
dictors of six-month mortality in patients with inferior MI.
Meta-analysis. Studies of RV myocardial involvement
were identified from a computerized search of the
MEDLINE data base between January 1966 and June
1999, reference lists and conference proceedings. Studies
were selected by two independent reviewers, and disagree-
ments were resolved by discussion. In order to be included,
studies had to meet the following criteria: 1) include at least
50 patients with RV myocardial involvement; and 2) report
clinical complications including mortality in patients with
inferior MI with and without RV myocardial involvement.
Six studies (including the present study) met our inclusion
criteria. Data on clinical complications, death, cardiogenic
shock, sustained ventricular tachycardia (VT) or ventricular
fibrillation (VF) and advanced (second- or third-degree)
atrioventricular block were extracted from each study and
pooled using the Peto-Yusuf modification of the Mantel-
Haenszel method under a fixed-effects model (5). Results
are presented as odds ratios (OR) and 95% confidence
intervals (CI), together with results of formal statistical
testing for heterogeneity.
RESULTS
A total of 491 patients with RV myocardial involvement,
638 patients without RV myocardial involvement and 974
patients with anterior MI were studied. Ninety-six percent
of patients received thrombolytic therapy.
Baseline characteristics. Table 1 summarizes the baseline
characteristics for each of the MI groups. There was a lower
proportion of males with RV myocardial involvement
(72.4%) than those without RV myocardial involvement
(80.4%) or anterior MI (79.1%) (p 5 0.001). The propor-
tion of smokers was higher in patients with (53.9%) and
without (52.7%) RV myocardial involvement than in those
with anterior MI (42%) (p 5 0.001), whereas patients
without RV myocardial involvement were more likely to
have undergone previous coronary artery bypass graft sur-
gery (5.3%) than those with RV myocardial involvement
(2.7%) or anterior MI (2.8%) (p 5 0.009). There was also a
significant difference in the distribution of Killip class
among the three groups, with a greater proportion of
patients with anterior MI and RV myocardial involvement
in Killip class 3 and 4 than patients without RV myocardial
involvement. Patients with RV myocardial involvement had
significantly lower systolic blood pressure (123 mm Hg)
compared with patients without RV myocardial involve-
ment (129.9 mm Hg) or anterior MI (134.4 mm Hg) (p 5
0.001).
Abbreviations and Acronyms
CK 5 creatine kinase
CORE 5 Collaborative Organization
for RheothRx Evaluation
trial
LV 5 left ventricle or ventricular
MI 5 myocardial infarction
RNA 5 radionuclide angiography
RV 5 right ventricular
99mTc-sestamibi SPECT 5 99mTechnetium Sestamibi
Single-Photon Emission
Computerized Tomography
VF 5 ventricular fibrillation
VT 5 ventricular tachycardia
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Mortality, pump failure and mechanical complications.
Mortality at hospital discharge, 35 days and 6 months was
highest in patients with anterior MI (9.7%, 10.6% and
13.2%, respectively), intermediate in patients with RV
myocardial involvement (7.1%, 7.5% and 8.9%, respectively)
and lowest in patients without RV myocardial involvement
(5.5%, 5.6% and 6.9%, respectively) (Table 2).
The incidences of in-hospital pump failure and mechan-
ical complications are presented in Table 2. There was no
significant difference in the incidence of left heart failure
between patients with and those without RV myocardial
involvement (OR 1.0, 95% CI 0.7 to 1.5), but the pooled
incidence of left heart failure in these two groups was
significantly lower than that in patients with anterior MI
(11.6% vs. 17.7%, p , 0.05). Patients with RV myocardial
involvement had a significantly higher incidence of hypo-
tension requiring therapy compared with patients without
RV myocardial involvement (OR 1.7, 95% CI 1.3 to 2.3) or
anterior MI (OR 2.1, 95% CI 1.6 to 2.8). There was also a
trend toward higher rates of cardiogenic shock in patients
with RV myocardial involvement as compared with those
without it (OR 1.3, 95% CI 0.8 to 2.1). The risk of cardiac
rupture was intermediate in patients with RV myocardial
involvement (0.8%) as compared with those with anterior
MI (1.5%) and those without RV myocardial involvement
Table 1. Baseline Characteristics for Patients With Anterior
Infarction and Inferior Infarction With and Without Right
Ventricular Involvement
Characteristics
Anterior
MI
(n 5 974)
Inferior MI
p
Value
RVMI
(n 5 491)
No
RVMI
(n 5 638)
Age (yr) 59.6 59.7 58.4 NS
Gender (% male) 79.1 72.4 80.4 0.001
Angina (%) 38.2 39.7 38.8 0.055
Myocardial infarction (%) 17.3 16.7 15.9 NS
Heart failure (%) 3.5 2.2 2.4 NS
Hypertension (%) 42.2 47.1 44.1 NS
Diabetes (%) 18.3 16.1 13.7 NS
Hyperlipidemia (%) 25.2 28.3 27.9 NS
CABG (%) 2.8 2.7 5.3 0.009
PTCA (%) 2.9 4.7 4.6 NS
Current smoker (%) 42.0 53.9 52.7 0.001
Thrombolytic therapy (%) 95.6 96.1 94.4 NS
Killip class (%)
1 55.2 62.2 67.0 0.001
2 31.9 28.6 25.2
3 6.8 4.1 3.5
4 6.1 5.1 4.4
Systolic BP (mm Hg) 134.4 123.0 129.9 0.001
Diastolic BP (mm Hg) 83.2 79.2 79.5 NS
BP 5 blood pressure; CABG 5 coronary artery bypass graft surgery; MI 5
myocardial infarction; PTCA 5 percutaneous transluminal coronary angioplasty;
RVMI 5 right ventricular myocardial involvement.
Table 2. Mortality and Other Complications During Hospital Period
Anterior
MI (%)
(n 5 971)
Inferior MI (%) Odds Ratio (95% CI)
RVMI
(n 5 491)
No
RVMI
(n 5 638)
RVMI vs.
No RVMI
RVMI vs.
Anterior MI
No RVMI vs.
Anterior MI
Mortality
In-hospital 9.7 7.1 5.5 1.3 0.7 0.5*
(0.8–2.1) (0.5–1.1) (0.4–0.8)
At 35 days 10.6 7.5 5.6 1.4 0.7 0.5†
(0.8–2.2) (0.5–1.0) (0.3–0.8)
At 6 months 13.2 8.9 6.9 1.3 0.6* 0.5‡
(0.9–2.0) (0.4–0.9) (0.3–0.7)
Pump failure or mechanical
complications
Left heart failure 17.7 11.7 11.5 1.0 0.6* 0.6†
(0.7–1.5) (0.4–0.8) (0.4–0.8)
Cardiogenic shock 7.8 6.9 5.5 1.3 0.9 0.7
(0.8–2.1) (0.6–1.3) (0.4–1.0)
Cardiac rupture 1.5 0.8 0.3 2.6 0.5 0.2*
(0.5–14.4) (0.2–1.6) (0.04–0.9)
Hypotension§ 16.1 29.0 19.3 1.7‡ 2.1‡ 1.2
(1.3–2.3) (1.6–2.8) (1.0–1.6)
Electrical complications
Atrial fibrillation 8.3 12.5 2.2 1.6 1.6 1.0
(1.1–2.4) (1.1–2.3) (0.9–1.4)
Ventricular fibrillation 5.0 8.4 2.7 3.3‡ 1.7 0.5\
(1.9–6.0) (1.1–2.7) (0.3–0.9)
Sustained VT¶ 4.4 6.8 2.7 2.6† 1.6 0.6
(1.4–4.8) (1.0–2.5) (0.3–1.0)
2° or 3° AV block 3.1 21.0 9.1 2.7‡ 8.4 3.2‡
(1.9–3.7) (5.5–12.8) (2.0–5.0)
*p , 0.01. †p , 0.001. ‡p , 0.0001. \p , 0.05. §Persistent hypotension requiring therapy. ¶.120 beats/min for .30 s.
AV 5 atrioventricular; CI 5 confidence interval; VT 5 ventricular fibrillation; other abbreviations as in Table 1.
39JACC Vol. 37, No. 1, 2001 Mehta et al.
January 2001:37–43 Prognostic Impact of Right Ventricular Infarction
(0.3%). Cardiac rupture was significantly less common in
patients without RV myocardial involvement as compared
with those with anterior MI (OR 0.2, 95% CI 0.04 to 0.9).
Reinfarction was not significantly different between patients
with RV myocardial involvement (6.9%), those without RV
myocardial involvement (7.7%) or those with anterior MI
(5.5%). Similarly, there were no significant differences in
postinfarction angina between the three groups (32.6%,
31.0% and 31.5%, respectively).
Electrical complications. The incidence of all serious ar-
rhythmic complications was significantly higher in patients
with RV myocardial involvement than in patients without
RV myocardial involvement or those with anterior MI
(Table 2). The risk of each of these arrhythmias was
intermediate in patients with anterior MI and lowest in
patients with inferior MI without RV myocardial involve-
ment, except for 2° or 3° atrioventricular block, which was
intermediate in patients without RV myocardial involve-
ment and lowest in patients with anterior MI.
Infarct size, LV ejection fraction and LV end-systolic
volume. Figure 1 displays the results of LV infarct size, as
determined by SPECT and peak CK, and of LV function
(LV ejection fraction and LV end-systolic volume), as
determined by RNA. There was a consistent pattern for all
four measures: LV infarct size was greatest and LV function
was least in patients with anterior MI as compared with
those with inferior MI with or without RV myocardial
involvement, but there was no difference in LV infarct size
or LV function between patients with and those without RV
myocardial involvement.
Predictors of poor outcome in inferior MI. The indepen-
dent predictors of six-month mortality in patients with
inferior MI are shown in Table 3. The presence of RV
myocardial involvement was a powerful and independent
predictor of six-month mortality. Other significant predic-
tors included age, female gender, diabetes, angina and
stroke. There appeared to an interaction between RV
myocardial involvement and age. Treatment allocation
(RheothRx or placebo) was not a significant predictor of
mortality in our model.
Figure 1. A, Left ventricular infarct size as measured by 99mTc-sestamibi SPECT perfusion imaging. B, Left ventricular ejection fraction (LVEF) as
measured by RNA. C, Left ventricular end-systolic volume (LVESV) as measured by RNA. D, Peak CK. RVMI1 and RVMI2 refer to patients with
inferior MI with and without right ventricular myocardial involvement, respectively.
Table 3. Independent Predictors of Six-Month Mortality in
Inferior Myocardial Infarction*
Variable
Regression
Coefficient
Standard
Error
p
Value
RVMI 6.9 1.74 0.0001
Age 0.12† 0.02 0.0001
Female gender 0.71 0.25 , 0.004
Diabetes 0.77 0.27 , 0.005
Angina 0.72 0.24 0.003
Stroke 1.0 0.41 0.01
AgezRVMI 0.10 0.03 0.0001
*Treatment (RheothRx or placebo) was not a significant predictor of mortality and
was not included in the final model. †For a one-year increase.
RVMI 5 right ventricular myocardial involvement.
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Meta-analysis. Six studies (including ours), involving a
total of 1,198 patients with RV myocardial involvement,
met our inclusion criteria (6–10). Compared with patients
who did not have RV myocardial involvement, those with
RV myocardial involvement were at significantly in-
creased risk of death (OR 3.2, 95% CI 2.4 to 4.1),
cardiogenic shock (OR 3.2, 95% CI 2.4 to 4.3), sustained
VT or VF (OR 2.7, 95% CI 2.1 to 3.5) and advanced
atrioventricular block (OR 3.4, 95% CI 2.7 to 4.2), with
relatively narrow CIs (Fig. 2). There was no difference in
reinfarction rates between the two groups (OR 1.1, 95%
CI 0.83 to 1.53).
DISCUSSION
To our knowledge, this is the single largest study to date
that has evaluated the prognostic impact of RV myocardial
involvement in patients with inferior MI. When combined
with the results of previous smaller studies, the pooled
clinical data provide clear evidence that patients with
inferior MI who have RV myocardial involvement are at
substantially increased risk of major complications, includ-
ing death, cardiogenic shock and ventricular arrhythmias.
Meanwhile, the lack of a difference in LV infarct size and
function between these two groups, as demonstrated in our
Figure 2. Meta-analysis of studies of right ventricular (RV) myocardial involvement/infarction. A, Mortality. B, Cardiogenic shock. C, Sustained VT or
VF. D, Advanced atrioventricular block. The horizontal axis represents log odds ratio with 95% confidence interval (CI). RVMI1 and RVMI2 refer to
patients with inferior MI with and without right ventricular myocardial involvement, respectively. RVMI 5 right ventricular myocardial infarction.
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study, indicates that the adverse prognosis in patients with
RV myocardial involvement is not simply due to more
extensive infarction of the LV; rather, it appears to be due
directly to involvement of the RV.
Previous studies examining the prognostic impact of RV
myocardial involvement in patients with inferior MI have
involved small numbers of patients with very few outcome
events (6–13). However, despite being the largest study to
date, the point estimates in our study were also associated
with wide confidence intervals, making it difficult to provide
precise estimates of the increased risk of mortality and other
complications associated with RV myocardial involvement.
Therefore, to obtain a more reliable estimate of risk, we
pooled the results from all of the studies performed to date
in the form of a meta-analysis. Our meta-analysis clearly
demonstrated that RV myocardial involvement was associ-
ated with a threefold increase in mortality, cardiogenic
shock and serious arrhythmias, with narrow confidence
limits.
The worse prognosis in patients with RV myocardial
involvement may be related to the increased risk of life-
threatening ventricular arrhythmias in these patients. Al-
though atrioventricular block is a widely recognized com-
plication of RV myocardial involvement (1,14), we also
found clear increases in sustained VT and VF (2.7-fold) in
these patients. This suggests that the RV may be more
arrhythmogenic than the LV—a hypothesis that warrants
further investigation.
Despite the higher risk of clinical complications in
patients with inferior MI who also had RV myocardial
involvement, our study demonstrated that LV infarct size
and function were similar between patients with and those
without RV myocardial involvement. Meanwhile, RV myo-
cardial involvement remained an independent predictor of
clinical outcome after adjustment for differences in baseline
characteristics between patients with and those without RV
myocardial involvement. These findings are consistent with
those of a previous study of RV infarction in an elderly
cohort, which demonstrated an independent association
between RV myocardial involvement and in-hospital death,
even after adjustment for LV ejection fraction (9). When we
compared patients with RV myocardial involvement and
patients with anterior MI, infarct size was significantly
smaller and LV ejection fraction was higher, but patients
with RV myocardial involvement still had significantly more
atrial fibrillation, VT/VF, third-degree block and hypoten-
sion. Furthermore, these worse outcomes were not related
to recurrent ischemia or reinfarction, which were similar
among all of the groups.
Study limitations. Our study has several potential limita-
tions. First, although it was our intent to obtain a lead V4R
in all patients with inferior MI, ;30% of patients present-
ing with inferior MI did not have lead V4R analysis.
However, there were no important differences in baseline
characteristics between patients who did and those who did
not have lead V4R analysis, suggesting that our study group
was representative of the overall population of patients with
inferior MI. Second, the diagnosis of RV myocardial in-
volvement was based on ECG criteria alone, even though
RV myocardial involvement is often considered to be a
clinical syndrome in which hypotension and elevated right-
sided pressure are required to make the diagnosis. However,
ST segment elevation in lead V4R has been shown in
previous studies to be highly sensitive as well as specific for
RV dysfunction in acute inferior MI (7,15–17). Finally,
selection bias is a potential limitation of this study because
of the nonconsecutive recruitment of patients. However,
large differences in outcomes between patients with and
those without RV myocardial involvement were observed
even within the constraints of a randomized trial data base
and may be expected to be even larger in everyday clinical
practice.
Clinical implications. Our study suggests that right-sided
precordial leads should be performed in all patients present-
ing with acute inferior MI, rather than only in patients
thought to have large infarctions. The routine adoption of
this approach will facilitate the early identification of pa-
tients with RV myocardial involvement who are at high risk
of life-threatening complications and who may warrant
more aggressive treatment. Recent data suggest that suc-
cessful reperfusion with primary coronary angioplasty can
achieve dramatic improvements in RV performance and
improved clinical outcomes in patients with RV myocardial
involvement (18). However, whether this strategy is supe-
rior to thrombolytic therapy in this patient group remains to
be demonstrated and awaits evaluation within the context of
a randomized trial.
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